Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Gestational diabetes mellitus (GDM) is a condition that develops during pregnancy when the body is not able to make enough insulin. GDM affects 2-10% of women during pregnancy.It is important to recognize and treat gestational diabetes as soon as possible to minimize the risk of complications to mother and baby.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Introduction to Gestational Diabetes MellitusSumi Singh
GDM - Gestational diabetes mellitus (GDM) is a condition in which a hormone made by the placenta prevents the body from using insulin effectively. Glucose builds up in the blood instead of being absorbed by the cells.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Gestational diabetes mellitus (GDM) is a condition that develops during pregnancy when the body is not able to make enough insulin. GDM affects 2-10% of women during pregnancy.It is important to recognize and treat gestational diabetes as soon as possible to minimize the risk of complications to mother and baby.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Introduction to Gestational Diabetes MellitusSumi Singh
GDM - Gestational diabetes mellitus (GDM) is a condition in which a hormone made by the placenta prevents the body from using insulin effectively. Glucose builds up in the blood instead of being absorbed by the cells.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
This talk was delivered for postgraduates and faculty of Dr. TMA Pai Hospital, Udupi on 07 March, 2017. This talk covered pathophysiology, screening, diagnosis, complications and management of diabetes mellitus in pregnancy.
Gestational Diabetes is a kind of diabetes that only pregnant women get.If a woman get diabetes or high blood sugar when she is pregnant, but she never had it before, then she has gestational diabetes.
The Primary Care Physician's guide to management of Pregnancy DiabetesHanifullah Khan
A guide on the screening, diagnosis and management of diabetes in pregnancy aimed at facilitating the handling of this condition in a primary care setting. Includes details on medications and dosages
This talk was delivered for postgraduates and faculty of Dr. TMA Pai Hospital, Udupi on 07 March, 2017. This talk covered pathophysiology, screening, diagnosis, complications and management of diabetes mellitus in pregnancy.
Gestational Diabetes is a kind of diabetes that only pregnant women get.If a woman get diabetes or high blood sugar when she is pregnant, but she never had it before, then she has gestational diabetes.
The Primary Care Physician's guide to management of Pregnancy DiabetesHanifullah Khan
A guide on the screening, diagnosis and management of diabetes in pregnancy aimed at facilitating the handling of this condition in a primary care setting. Includes details on medications and dosages
Gestational diabetes mellitus is carbohydrate intolerance with onset or first recognition during pregnancy. In affects up to 14 of the pregnant population. The main pathogenic factor is insulin resistance , which occurs to same degree in all pregnancies, but those who are unable to compensate develop gestational diabetes mellitus.
Diabetes mellitus:
Diabetes mellitus is a clinical syndrome characterized by hypoglycemia due to absolute or relative deficiency of insulin.
Gestational diabetes mellitus:
Gestational diabetes mellitus can be defined as diabetes that appears in pregnancy for the first time in a previously non – diabetic patient and disappears after delivery.
Causes:
1. Hormonal imbalance
2. High blood sugar
3. The pancreas produce less effective insulin
It is a presentation on GDM 2023.
Our aim is to reduce morbidity and mortality related to Non communicable diseases such as hypertension, diabetes, cardiovascular disease, stroke, Obesity, Cancer and lifestyle diseases among those least able to withstand the burden of the disease.
Our aim is to reduce morbidity and mortality related to Non communicable diseases such as hypertension, diabetes, cardiovascular disease, stroke, Obesity, Cancer and lifestyle diseases among those least able to withstand the burden of the disease.
Our aim is to reduce morbidity and mortality related to Non communicable diseases such as hypertension, diabetes, cardiovascular disease, stroke, Obesity, Cancer and lifestyle diseases among those least able to withstand the burden of the disease.
Our aim is to reduce morbidity and mortality related to Non communicable diseases such as hypertension, diabetes, cardiovascular disease, stroke, Obesity, Cancer and lifestyle diseases among those least able to withstand the burden of the disease.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
The WDF mission:
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries.
For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources.
The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
The WDF mission:
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
More from Jain hospital,Mahavir Sikshan Sansthan (20)
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
2. Objectives
Discuss causes, prevention strategies and
treatment of hypoglycemia for those women on
insulin
Discuss premature labour, recognizing
contractions, and action to take
Discuss diagnosis and treatment of preeclampsia
2
3. Definition of hypoglycemia
1. The development of autonomic or
neuroglycopenic symptoms
2. Low plasma glucose (less than 4.0 mmol/L or
72 mg/dl)
3. Symptoms resolved by administration of
carbohydrate
Cryer, Davis, Shamoon, 2003
3
4. Risk of hypoglycemia (1 of 3)
Only those taking glucose-lowering medicines
or insulin are at risk
Risk increases with:
• Not enough carbohydrate consumption
• Late or missed meal
• Fasting or malnourishment
• Too much insulin
• Prolonged or unplanned activity
4
8. Effect Of Hypoglycemia On Fetus
Fetal heart rate, as well as fetal movements
and placental perfusion appear to be
unchanged during conditions of maternal
hypoglycemia in the range of 2.5 – 3.0 mmol/L
(45–55 mg/dL)
Coustan, 2009
Diamond, Reece et al, 1992
Nisell, Persson, et al1994
Reece, Hagav, et al 1995
8
10. Treatment
Severe
• 20 g glucose
• Glucagon 1ml SC or IM; increases BG by 3 -12 mmol/L
(54-216 mg/dl) over 60 min
• IV dextrose- 20 to 50 ml of 50% dextrose over 2 to 3
minutes; immediate response is seen
• Manage seizure- place person on their side if not too
agitated
10
11. Follow-up management
• Meal or snack (15 to 20 g carbohydrate + a protein
source)
• Next dose of insulin taken as usual if cause is known
and hypo was mild
• Consider reducing next dose of insulin if hypo was
severe
• Assess cause and prevent recurrence
• Avoid BG levels < 4 mmol/L (72 mg/dL)
11
12. Premature Labour
Preterm labour in GDM – can use steroids and
tocolysis as for other pregnancies
Preferably avoid betamimetic as tocolytics
Nifidepine is a good choice
Both steroids / tocolytics can push glucose up so
need to monitor closely and cover with insulin /
increasing dose of insulin
Rule out UTI as a risk factor for preterm labour
12
13. Preeclampsia
• Women with GDM are at increased risk of
preeclampsia; this is partly due to the
increased insulin resistance
• It is possible that this increase could be
accounted for by the fact that their age and
BMI predispose them to GDM as well as
hypertension.
• Monitor BP & urine albumin every visit
Hollander 2007
13
15. Objectives
Discuss when to deliver infant
Discuss options for inducing labour
Discuss implications of Caesarian section
15
16. Timing of delivery – the same for all?
• Women with diabetes before pregnancy are at
increased risk
• In GDM perinatal mortality rates lower
• If insulin requiring, best to use approach similar to
pregestational DM
• GDM managed on diet and exercise alone possibly not
at any greater risk from baseline
• Depends on severity and duration of diabetes as well as
co morbidities
16
18. Consider….
Gestational specific risks for still birth continue to
fall up to 38 weeks but increase slightly over 40
weeks
In insulin dependent women most would plan
delivery 38 - 39 weeks
Between 38 and 39 weeks
No difference in incidence of cesareans
More larger babies in one study
There is as yet not enough evidence that induction in
diabetic pregnancies prevents fetal macrosomia
18
19. In diet controlled GDM women most would be
comfortable to 40 weeks
With good control and reassuring tests of well
being some centres go on to 41 weeks
Patel, Steer, Doyle et al. 2003
19
20. Mode of delivery
Matter of choice
High section rates – 30 – 80% averaging 50% in
many centres
Vaginal delivery is possible and safe
Previous obstetric history
EFW
Other clinical factors
Induction of labour is a safe option
20
21. Monitoring labour
Labour is a time of unpredictable glucose and insulin
demands – risk of hypoglycemia
Sliding scale / infusion
Maintain plasma glucose below 110 mg/dl to avoid maternal
hyperglycemia and subsequent foetal hypoglycemia
Careful intrapartum FHR monitoring
Pay attention to second stage – slow progress is a
red flag
Caution with instrumental delivery
Be prepared for shoulder dystocia
Jovanovic L. 2005
21
22. References
COMPLICATIONS
Canadian Diabetes Association Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines
for the Prevention and Management of Diabetes in Canada. Can J Diab 2013;37(suppl 1):S69-71
Coustan, D, Glob. libr. women's med., (ISSN: 1756-2228) 2009; DOI 10.3843/GLOWM.10162
Cryer P.E. Davis, S.N. Shamoon, H. Hypoglycemia in diabetes. Diabetes Care, 2003;26(6):1902-1912
Diamond MP, Reece EA, Caprio S et al: Impairment of counterregulatory hormone responses to hypoglycemia in
pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1992;166:70-77
Hollander M, Paarlberg KM, Huisjes AJM, 2007 Gestational Diabetes: A Review of the Current Literature and
Guidelines Volume 62, Number 2 Obstetrical and Gynecological Survey
Nisell H, Persson B, Hanson U, et al: Hormonal, metabolic and circulatory responses to insulin-induced hypoglycemia
in pregnant and nonpregnant women with insulin-dependent diabetes. Am J Perinatol 1994;11:231-236
Reece EA, Hagay Z, Roberts AB et al: Fetal Doppler and behavioral responses during hypoglycemia induced with the
insulin clamp technique in pregnant diabetic women. Am J Obstet Gynecol 1995;172:151-155.
Saleh M., Grunberger, G. Hypoglycemia: A cause for poor glycemic control. Clinical Diabetes, 2001;19(4):161-167.
DELIVERY
Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early
normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28:1113.
Patel RR, Steer P, Doyle P, Little MP, Elliot P. Does gestation vary by ethnic group? A London-based study of over
122000 pregnancies with spontaneous onset of labour. Int J of Epid. 2003;33:107-113.DOI: 10.1093/ijc/dyg238.
22
Editor's Notes
Cryer P.E. Davis, S.N. Shamoon, H. (2003). Hypoglycemia in diabetes. Diabetes Care, 26(6),1902-1912
Severe hypoglycaemia is more common following a previous episode of hypoglycaemia. This is because the normal subsequent counter-regulatory responses are blunted. It may also be that a person did not consume adequate carbohydrate in response to the initial hypoglycaemia.
People who have frequent mild to moderate hypoglycaemic reactions may also have blunted glucagon response putting them at risk for severe hypoglycemia.
Overcorrection of elevated blood glucose levels is a very common cause of hypoglycaemia. It is difficult to predict the effect of stress on blood glucose levels.
Women with type 1 diabetes in their first trimester of pregnancy – particularly during weeks eight to 12 – often experience wide swings in blood glucose levels, including many low levels. Breastfeeding women are also at higher risk. Safety is a major concern; they should always eat before driving, for instance, and always test before feeding or bathing the baby.
Comorbidities such as gastroparesis, liver disease or kidney failure may increase the risk of hypoglycaemia. Gastroparesis results in delayed gastric emptying and therefore delays the uptake of glucose. If medication has been taken, this may work before the glucose reaches the blood. Liver or kidney disease may alter the clearance of medicines and provoke prolonged action or build up of glucose-lowering medicines.
Physiology forms the basis for definitions of low levels of blood glucose as “mild’’, “moderate’’ and “severe’’.
It is important to assess hypoglycaemia in terms of incidence, realistic prevention goals and treatment.
We should hope to prevent all severe hypoglycaemia. However, some mild-to-moderate hypoglycaemia must be expected given the current available diabetes treatments.
Canadian Diabetes Association Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diab 2013;37(suppl 1):S69-71
People with diabetes, their families and healthcare providers fear hypoglycaemia.
Their fears are justified: hypoglycaemia has social and health implications. People with diabetes who are hypoglycaemic may act “inappropriately’’ or appear drunk. The treatment of hypoglycaemia may also cause embarrassment. (Cryer, 2003)
Presenting symptoms of hypoglycaemia are very troubling and frightening.
Moreover, hypoglycaemia can lead to injury, such as falling and fracturing bones; an accident while driving – possibly resulting in loss of driving license as well as any physical consequences; cognitive impairment; and on rare occasions death.
Hypoglycaemia, severe hypoglycaemia in particular, may be a major limitation to achieving desired goals of blood glucose control.
Cryer P.E. Davis, S.N. Shamoon, H. (2003). Hypoglycemia in diabetes. Diabetes Care, 26(6),1902-1912
Saleh M., Grunberger, G. (2001). Hypoglycemia: A cause for poor glycemic control. Clinical Diabetes, 19(4), 161-167.
Coustan, D, Glob. libr. women's med., (ISSN: 1756-2228) 2009; DOI 10.3843/GLOWM.10162
Diamond MP, Reece EA, Caprio S et al: Impairment of counterregulatory hormone responses to hypoglycemia in pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 1992;166:70-77.
Nisell H, Persson B, Hanson U, et al: Hormonal, metabolic and circulatory responses to insulin-induced hypoglycemia in pregnant and nonpregnant women with insulin-dependent diabetes. Am J Perinatol 1994;11:231-236.
Reece EA, Hagay Z, Roberts AB et al: Fetal Doppler and behavioral responses during hypoglycemia induced with the insulin clamp technique in pregnant diabetic women. Am J Obstet Gynecol 1995;172:151-155.
Hypoglycaemia must be treated quickly. If possible, blood glucose levels should be measured with a meter to confirm hypoglycaemia. Do not delay treatment. If a meter is not available, treat the symptoms.
If hypoglycemia occurs before a meal, it should be treated then the meal taken as usual.
After treatment, wait 15 minutes before testing again. If blood glucose remains lower than 4 mmol/L (72 mg/dL), glucose should be consumed.
Through fear or impatience, people have a tendency to over-treat hypoglycaemia. People with diabetes and healthcare professionals should learn not to over-treat; the blood glucose may get too high. This is known as rebound hyperglycemia.
This slide shows examples of treatment of mild or moderate hypoglycaemia. The recommended measures are:
Glucose tablets or glucose gel if available
1/2 (125 mls) cup fruit juice
150 mls soft drink
3 teaspoons sugar or honey
1 cup of milk
Glucose should be given in a quickly absorbed form – that is as “straight’’ sugar.
Canadian Diabetes Association Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diab 2013;37(suppl 1):S69-71
It is not advisable to repeat the glucagon; after a single dose, the person with diabetes will usually be able to take further glucose orally. If not, an ambulance should be called or the person transported to a hospital.
In people with severe hypoglycaemia, when confusion or loss of consciousness prevents self-management, it is imperative to ensure their airway is clear before administering a form of glucose.
If there is no glucagon available, and the person is not able to take fluids, honey or sugar substance could be smeared on the buccal mucosa. This has been shown not to work very well but when there is no other option it is worth trying.
Treatment should be followed by the planned snack or meal. If the usual meal or snack is not planned for another hour or more, a snack consisting of carbohydrate (15-20 g) and protein may be needed.
In mild to moderate hypoglycaemia, the next dose of diabetes medication or insulin is usually given. However, this should be individually assessed depending on the cause of the hypoglycaemia and the severity of the episode.
After a severe episode, the next dose of insulin would likely be omitted or reduced by an amount predetermined by the health professional – by about 20% for 24 or 48 hours, for example.
Although the causes of 50% of hypoglycaemic events are unknown, people with diabetes should be encouraged to try to determine the cause of hypoglycaemia and adjust treatment or lifestyle accordingly to prevent this occurring in the future.
There may be iatrogenic prematurity in GDM or type 1 – if glucose levels are very high the decision may be taken to deliver before 37 weeks.
Hollander M, Paarlberg KM, Huisjes AJM, 2007 Gestational Diabetes: A Review of the Current Literature and Guidelines Volume 62, Number 2 Obstetrical and Gynecological Survey
In women with GDM, infant mortality rates at 39 weeks are lower than the overall mortality risk of expectant management for 1 week; absolute risks of stillbirth and infant death are low.
http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=22464068
In India, most will not allow beyond 40 weeks even if on diet alone and well controlled. ( ref of Indian babies maturing faster/ more meconium etc)
Patel RR, Steer P, Doyle P, Little MP, Elliot P. Does gestation vary by ethnic group? A London-based study of over 122000 pregnancies with spontaneous onset of labour. Int J of Epid. 2003;33:107-113.DOI: 10.1093/ijc/dyg238.
Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28:1113.